Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
MSB11455
DRUG
2 trials
Sponsors
Fresenius Kabi SwissBioSim GmbH
Conditions
Healthy
Phase 1
Safety and Immunogenicity of MSB11455 in Healthy Participants
Completed
NCT03251339
Fresenius Kabi SwissBioSim GmbH
Healthy
Start: 2017-08-21
End: 2018-09-22
Updated: 2019-07-02
Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects
Completed
NCT03251248
Fresenius Kabi SwissBioSim GmbH
Healthy
Start: 2017-08-22
End: 2018-10-17
Updated: 2019-07-02
Related Papers
Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial
Clinical Therapeutics
2020-07-11
5 citations
Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial.
Journal of Clinical Oncology
2019-05-20
1 citations